+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antisense Oligonucleotide"

Technology Growth Opportunities for Exosome-Mediated Drug Delivery - Product Thumbnail Image

Technology Growth Opportunities for Exosome-Mediated Drug Delivery

  • Report
  • September 2022
  • 62 Pages
  • Global
From
Technological Advances in RNA Stabilization & Delivery - Product Thumbnail Image

Technological Advances in RNA Stabilization & Delivery

  • Report
  • November 2021
  • 73 Pages
  • Global
From
From
RNA Technology Driving the New Wave of Therapeutics - Product Thumbnail Image

RNA Technology Driving the New Wave of Therapeutics

  • Report
  • September 2018
  • 15 Pages
  • Global
Innovations in RNA Interference and MicroRNA Therapies - Product Thumbnail Image

Innovations in RNA Interference and MicroRNA Therapies

  • Report
  • April 2018
  • 15 Pages
  • Global
From
From
From
From
From
From
Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020 - Product Thumbnail Image

Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 39 Pages
  • Global
From
Loading Indicator

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body. The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more